USA - March 30 2021
According to the Federal Circuit, $173 million was the right damages award for almost three years of patent infringement resulting from Baxalta’s…
Jordan Engelhardt, Aron Fischer
USA - March 8 2021
The fight over proposed Enbrel® (etanercept) biosimilar Erelzi® continues. Sandoz Inc., Sandoz International GmbH and Sandoz GmbH (“Sandoz”) recently…
Jordan Engelhardt
USA - March 2 2021
On February 9, 2021, United States Magistrate Judge Ramon E. Reyes, Jr. (E.D.N.Y.) recommended that Sell Below Cost USA LLC’s (“Sell Below”) DJ…
Lewis V. Popovski
USA - February 18 2021
The Federal Circuit considered its 35 U.S.C. § 112 enablement case law and found that “the enablement inquiry for claims that include functional…
Andrew D. Cohen
USA - February 9 2021
On February 5, 2021, the FDA approved Juno Therapeutics, Inc.’s Breyanzi® (lisocabtagene maraleucel) for “treatment of adult patients with relapsed…
Jordan Engelhardt